Infant Formula Recall Retirada del mercado de fórmula infantil

ALERT: ByHeart Recalls Whole Nutrition Infant Formula. Read more

AVISO IMPORTANTE: ByHeart retira del mercado su fórmula infantil Whole Nutrition. Aprender más

Transportation Update Actualización de transporte

Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.

Learn more here

For other questions, please call Member Services at the number on the back of your member ID card.

A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).

Obtenga más información AQUI

Si tiene otras preguntas, llame a Servicios para Miembros al número que aparece en la parte posterior de su tarjeta de identificación del miembro.

Search

Clinical Criteria Revision for Evkeeza® effective June 1, 2023

Date: May 18, 2023

Attention: All Providers

Effective Date: June 1, 2023

Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective June 1, 2023, Texas Health and Human Services (HHSC) will expand coverage for Evkeeza® (procedure code J1305) to adolescents 5 years of age and older due to a recent U.S. Food and Drug Administration (FDA) approval. Evkeeza® is an injectable prescription medicine used along with other low-density lipoprotein (LDL) lowering medicines in treating high cholesterol called homozygous familial hypercholesterolemia (HoFH).

How this impacts providers: Starting June 1, 2023, TCHP will expand the age requirement to adolescents 5 years of age and older. Refer to the Outpatient Drug Services Handbook Chapter of the Texas Medicaid Provider Procedure Manual for more details on the clinical policy and prior authorization requirements.

Next steps for providers: Prescribers should share this communication with their staff. It is important for providers to be aware of this new age indication. Providers will need to consider the dosage and administration for the younger population and monitor for any potential adverse effects. Providers must submit documentation (such as office chart notes, lab results, other pertinent clinical information, etc.) supporting that the member has met all appropriate criteria in support for Evkeeza® approval.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.

For access to all provider alerts, log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.